β-Hydroxyisovalerylshikonin and cisplatin act synergistically to inhibit growth and to induce apoptosis of human lung cancer DMS114 cells via a tyrosine kinase-dependent pathway

Oncology

Volumn 66, Issue 1, 2004, Pages 67-75

  Xu, Ying ^a   Kajimoto, Sachiko ^a   Nakajo, Shigeo ^a   Nakaya, Kazuyasu ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Hydroxyisovalerylshikonin; Cisplatin; Lung cancer cell; Synergism; Tyrosine kinases

Indexed keywords

(3 HYDROXYISOVALERYL)SHIKONIN; ANTIBODY; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHOTYROSINE SPECIFIC ANTIBODY; PROTEIN TYROSINE KINASE; SHIKONIN DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BETA-HYDROXYISOVALERYLSHIKONIN; NAPHTHOQUINONE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LUNG SMALL CELL CANCER; NICK END LABELING; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; CELL CULTURE; DRUG EFFECT; ENZYMOLOGY; LUNG TUMOR; METABOLISM; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CISPLATIN; DRUG SYNERGISM; HUMANS; IN SITU NICK-END LABELING; LUNG NEOPLASMS; NAPHTHOQUINONES; PROTEIN-TYROSINE KINASES; TUMOR CELLS, CULTURED;

EID: 1642525639     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076337     Document Type: Article

References (32)

1. Hunter T, Sefton BM: Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci USA 1980;77:1311-1315.
2. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-212.
3. Brown MT, Cooper JA: Regulation, substrates and functions of src. Biochim Biophys Acta 1996;1287:121-149.
4. Levitzki A, Gazit A: Tyrosine kinase inhibition: An approach to drug development. Science 1995;267:1782-1788.
5. Klijn JG, Berns PM, Schmitz PI, Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992;13:3-17.
6. Iihara K, Shiozaki H, Tahara H, Kobayashi K, Inoue M, Tamura S, et al: Prognostic significance of transforming growth factor-α in esophageal carcinoma. Implication for autocrine proliferation. Cancer 1993;71:2902-2909.
7. Hashimoto S, Xu M, Masuda Y, Aiuchi T, Nakajo S, Cao J, et al: β-Hydroxyisovalerylshikonin inhibits the cell growth of various cancer cell lines and induced apoptosis in leukemia HL60 cells through a mechanism different from those of Fas and etoposide. J Biochem 1999;125:17-23.
8. Hashimoto S, Xu Y, Masuda Y, Aiuchi T, Nakajo S, Uehara Y, et al: β-Hydroxyisovalerylshikonin is a novel and potent inhibitor of protein tyrosine kinases. Jpn J Cancer Res 2002;93:944-951.
9. Rosenberg B: Anticancer activity of cis-diamminedichloroplatinum (II) and some relevant chemistry. Cancer Treat Rep 1979;63:1433-1438.
10. Zwelling LA, Anderson T, Kohn KW: DNA-protein and DNA interstrand cross-linking by cis-and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxity. Cancer Res 1979;39:365-369.
11. Sorenson CM, Barry MA, Eastman A: Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990;82:749-755.
12. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995;92:7686-7689.
13. Alessi DR, Cuenda A, Cohen P, Dudley DT, Salitiel AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-27494.
14. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, et al: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-18632.
15. Chu G: Cellular responses to cisplatin. J Biol Chem 1994;269:787-790.
16. Petsko GA: Heavy metal revival. Nature 1995;377:580-581.
17. Aaronson SA: Growth factors and cancer. Science 1991;254:1146-1153.
18. Al-obeidi FA, Lam KS: Development of inhibitors for protein tyrosine kinases. Oncogene 2000;19:5690-5701.
19. Gianni M, Kalac Y, Ponzanelli I, Rambaldi A, Terao M, Garattini E: Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: Effects on the degradation of RARα and PML-RARα. Blood 2001;97:3234-3243.
20. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al: Effects of a selective inhibitor of Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566.
21. Sherwin SA, Minna JD, Gazdar AF, Todaro GJ: Expression of epidermal and nerve growth factor receptors and soft agar growth factor production by human lung cancer cells. Cancer Res 1981;41:3538-3542.
22. Merlino GT, Xu YH, Richert N, Clark AJ, Ishii S, Banks-Schlegel S, Pastan I: Elevated epidermal growth factor gene copy number and expression in a squamous carcinoma cell line. J Clin Invest 1985;75:1077-1079.
23. Haeder M, Rotsch M, Bepler G, Hennig C, Havemann K, Heimann B, et al: Epidermal growth factor expression in human cancer cell lines. Cancer Res 1988;48:1132-1136.
24. Rabiasz GJ, Langdon SP, Bartlett JM, Crew AJ, Miller EP, Scott WN, et al: Growth control by epidermal growth factor and transforming growth factor-alpha in human lung squamous carcinoma cells. Br J Cancer 1992;66:254-259.
25. Rachwal WJ, Bongiorno PF, Orringer MB, Whyte RI, Ethier SP, Beer DG: Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Br J Cancer 1995;72:56-64.
26. Suarez Pestana E, Greiser U, Sanchez B, Fernandez LE, Lage A, Perez R, et al: Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal factor receptor and by ganglioside GM3: Involvement of receptor-directed protein tyrosine phosphatase(s). Br J Cancer 1997;75:213-220.
27. Pavelic K, Banjac Z, Pavelic J, Spaventi S: Evidence for a role of EGF receptor in the progression of human lung cancer carcinoma. Anticancer Res 1993;13:1133-1138.
28. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, et al: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cells. Cancer Res 1991;51:4575-4580.
29. Fan Z, Baselga J, Masui H, Mendelsohn J: Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53:4637-4642.
30. c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 1994;54:3758-3765.
31. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ: Antibody to HER-2/neu receptor blocks after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-1838.
32. Gieseg MA, de Bock C, Ferguson LR, Denny WA: Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anticancer Drugs 2001:12:683-690.